Dual therapy with lamivudine + protease inhibitor during pregnancy for prevention of mother-to-child transmission of HIV-1

J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):e159-63. doi: 10.1097/QAI.0b013e31829b2c4b.

Authors

Smaranda S Gliga¹, Cyril O Clavel, Anne F Alix, Marc Dommergues, Frederique Quetin, Anne G Marcelin, Luminita Schneider, Hind Stitou, Ruxandra Calin, Fabienne Caby, Marc A Valantin, Christine Katlama, Roland Tubiana

Affiliation

¹ *Adulti III Departament, Matei Bals National Institute of Infectious Diseases, Bucharest, Romania †Departement de Gynecologie et Obstetrique, Hopital Pitie- Salpetriere, Paris, France ‡Internal Medecine Departament, Louis Constant Fleming Hospital, St Martin §Departement de Neonatologie, Hopital Pitie- Salpetriere, Paris, France ‖Laboratoire de Virologie, Hopital Pitie- Salpetriere, Paris, France ¶Inserm U943 Paris, France #Departement des Maladies Infectieuses et Tropicales, Hopital Pitie- Salpetriere, Paris, France.

PMID: 24135778
DOI: 10.1097/QAI.0b013e31829b2c4b

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Anti-HIV Agents / therapeutic use*
Drug Therapy, Combination / methods
Female
HIV Infections / drug therapy
HIV Infections / prevention & control*
HIV Infections / transmission*
HIV Protease Inhibitors / therapeutic use*
HIV-1 / isolation & purification
Humans
Infant, Newborn
Infectious Disease Transmission, Vertical / prevention & control*
Lamivudine / therapeutic use*
Plasma / virology
Pregnancy
Pregnancy Complications, Infectious / drug therapy*
Treatment Outcome
Viral Load

Substances

Anti-HIV Agents
HIV Protease Inhibitors
Lamivudine